AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years The study has completed patient recruitment ...
New MS treatments target myelin repair, neuroprotection, and CNS-resident immune cells, offering hope for progressive forms of the disease. Bruton tyrosine kinase inhibitors (BTKis) like tolebrutinib ...
Hosted on MSN
Multidisciplinary study finds estrogen could aid in therapies for progressive multiple sclerosis
About 100,000 of the estimated million people in the United States with multiple sclerosis (MS) have a progressive form of the disease, with symptoms that worsen continuously or after periods of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback